Prolyl hydroxylase domain-containing (PHD) enzyme inhibitors represent a new concept in treating CKD-associated anemia through the activation of the hypoxia-inducible factor (HIF) pathway and subsequent erythropoiesis (Mima, 2021). Here, PDC is linked to chronic kidney disease.